The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1B trial of ADI-PEG 20 (A) plus nab-Paclitaxel (nab-P) and gemcitabine (gem) in subjects with advanced pancreatic cancer (APC).
 
Maeve Aine Lowery
No Relationships to Disclose
 
Marinela Capanu
No Relationships to Disclose
 
Danielle C. Glassman
No Relationships to Disclose
 
Christina M. Covington
No Relationships to Disclose
 
Jill Gluskin
No Relationships to Disclose
 
Robin Brenner
No Relationships to Disclose
 
Chien-Feng Li
No Relationships to Disclose
 
John S. Bomalaski
No Relationships to Disclose
 
Amanda Johnston
Employment - Polaris
Stock and Other Ownership Interests - Polaris
Travel, Accommodations, Expenses - Polaris
 
Adalberto Barba
Research Funding - Polaris
 
Kenneth H. Yu
No Relationships to Disclose
 
David Paul Kelsen
No Relationships to Disclose
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Aduro Biotech (I); Astellas Pharma; AstraZeneca (I); Celgene; Celsion; cipla; Exelixis; IntegraGen; Jennerex; Lilly/ImClone; MedImmune; Novartis; Pharmacyclics (I); Sanofi (I); Silenseed (I); Vicus Therapeutics
Research Funding - Abbott Laboratories (Inst); Amgen (Inst); Bayer (Inst); Exelixis (Inst); Genentech (Inst); Lilly/ImClone (Inst); Novartis (Inst); Polaris (Inst); Roche (Inst); Vicus Therapeutics (Inst)
Travel, Accommodations, Expenses - Polaris
 
Leonard Saltz
Consulting or Advisory Role - Abbvie; Lilly; McNeil PPC (I); Roche/Genentech
Research Funding - Taiho Pharmaceutical
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Aduro Biotech; Astellas Pharma (I); Celgene; Celsion (I); Cipla; Exelixis (I); Gilead Sciences; Hexal (I); IntegraGen (I); Jennerex (I); Lilly (I); MedImmune; Merrimack; Novartis (I); Pharmacyclics; Sanofi; Silenseed; Vicus Therapeutics
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Immunomedics (Inst); Incyte (Inst); Momenta Pharmaceuticals (Inst); Myriad Genetics (Inst); OncoMed (Inst); Polaris (Inst); Sanofi (Inst)